The chest wall.

N. Barrett

DOI: https://doi.org/10.1055/b-0034-77873

Annals of The Royal College of Surgeons of England

Abstract:

What problem does this paper attempt to address?

High Expression of BCAT1 Sensitizes AML Cells to PARP Inhibitor by Suppressing DNA Damage Response

Jiajia Pan,Yungui Wang,Shujuan Huang,Shihui Mao,Qing Ling,Chenying Li,Fenglin Li,Mengxia Yu,Xin Huang,Jiansong Huang,Yunfei Lv,Xia Li,Wenle Ye,Huafeng Wang,Jinghan Wang,Jie Jin

DOI: https://doi.org/10.1007/s00109-023-02409-1

2024-01-01

Abstract:Previous evidence has confirmed that branched-chain aminotransferase-1 ( BCAT1 ), a key enzyme governing branched-chain amino acid (BCAA) metabolism, has a role in cancer aggression partly by restricting αKG levels and inhibiting the activities of the αKG -dependent enzyme family. The oncogenic role of BCAT1 , however, was not fully elucidated in acute myeloid leukemia (AML). In this study, we investigated the clinical significance and biological insight of BCAT1 in AML. Using q-PCR, we analyzed BCAT1 mRNAs in bone marrow samples from 332 patients with newly diagnosed AML. High BCAT1 expression independently predicts poor prognosis in patients with AML. We also established BCAT1 knockout (KO)/over-expressing (OE) AML cell lines to explore the underlying mechanisms. We found that BCAT1 affects cell proliferation and modulates cell cycle, cell apoptosis, and DNA damage/repair process. Additionally, we demonstrated that BCAT1 regulates histone methylation by reducing intracellular αKG levels in AML cells. Moreover, high expression of BCAT1 enhances the sensitivity of AML cells to the Poly (ADP-ribose) polymerase (PARP) inhibitor both in vivo and in vitro. Our study has demonstrated that BCAT1 expression can serve as a reliable predictor for AML patients, and PARP inhibitor BMN673 can be used as an effective treatment strategy for patients with high BCAT1 expression. Key messages High expression of BCAT1 is an independent risk factor for poor prognosis in patients with CN-AML. High BCAT1 expression in AML limits intracellular αKG levels, impairs αKG-dependent histone demethylase activity, and upregulates H3K9me3 levels. H3K9me3 inhibits ATM expression and blocks cellular DNA damage repair process. Increased sensitivity of BCAT1 high expression AML to PARP inhibitors may be used as an effective treatment strategy in AML patients.
High Expression of BCAT1 Promotes Acute Myeloid Leukemia Progression and Sensitize to PARP Inhibitor

Jie Jin,Jiajia Pan,Yungui Wang,Shujuan Huang,Shihui Mao,Qing Ling,Jinghan Wang,Chenying Li

DOI: https://doi.org/10.1182/blood-2019-125221

IF: 20.3

2019-01-01

Blood

Abstract:Acute myeloid leukemia (AML) is a highly heterogeneous disease with poor clinical prognosis, especially to cytogenetically normal AML(CN-AML)patients, which belong to moderate prognosis group. The clinical outcomes of them are not consistent. Therefore, further exploration of novel biomarkers and development of new anti-tumor drugs is urgently needed. Recently, accumulating evidence have emerged and demonstrated that branched-chain amino acids (BCAA) are essential for tumor growth and proliferation. Branched-chain aminotransferase 1(BCAT1), a BCAA metabolic enzyme, which correlates with cancer aggression, not only that, it has been reported that overexpression of BCAT1in leukemia cells decreased intracellular αKG levels, showed the characteristics of stem cells and displayed a phenotype like cases carrying IDH mutations. By limiting intracellular αKG, BCAT1high expression AML cells prone to cause an increase in DNA damage probably via suppressing homologous recombination. We firstly analyzed the prognostic significance of BCAT1expression in CN-AML patients. Collectively, we found that patients with high levels of BCAT1had poor prognosis, the median overall survival time is shorter in BCAT1high group (356 days versus 570 days)(Figure A). Next, we performed gene knockout in THP-1 and MV4-11 cells with relatively high expression of BCAT1and gene overexpressing in the relatively low expression cell line OCI-AML3. In summary, BCAT1overexpression contributed to cell growth, whereas suppression of BCAT1markedly limited cell proliferation and colony-forming ability by blocking cell circle at G0/G1 phase(Figure B and C).The mice model we conducted further validated the role of BCAT1expression in vitro. Notably, we found that knockout and overexpression of BCAT1can respectively reduce and enhance the tumor burden(Figure D)and effects the time of survival(Figure E). Because both BCAT1high expression and IDH mutation could decrease αKG levels and suppress αKG dependent dioxygenases, it is tempting to speculate that there is a possibility of a "BRCAness" phenotype when BCAT1is overexpressed.We indeed observed a rise in the base line level of DNA damage marker γ-H2AX in BCAT1overexpressing cell line(Figure F). In addition, the sensitivity of cells to cisplatin is also positively correlated with BCAT1expression levels, the IC50 of BCAT1overexpressing cell line OCI-AML3 is much lower than control. Consistently, knocking out of BCAT1decreased sensitivity to cisplatin. So we further tested the relationship between PARPi talazoparib(BMN 673) and BCAT1expression, Use a gain of function approach we increased susceptibility to PARPi, together with the loss of function data, these results strongly suggest that BCAT1promotes cell sensitivity to PARPi(Figure G). We believe that the combination of high expression of BCAT1and PARPi produces synthetic lethality. In addition, the ability to trap PARP1 of PARPi may produce unacceptable toxicity when combined with conventional doses of cytotoxic chemotherapies. So, we next combined PARP inhibitors with DNA-damaging agent daunorubicin, the synergistic effect is promising on BCAT1overexpressed OCI-AML3 cell especially at high dose, however, the synergistic effect of the control group is weak, sometimes even manifested as antagonistic.Consistent with previous reports, IDH1/2mutAML is vulnerable to PARP inhibition as monotherapy, but especially when combined with daunorubicin treatment. These results also confirmed our hypothesis that BCAT1overexpression mimics the phenotype of IDHmutcells, not only as DNA hypermethylation, but also leads to increased DNA damage levels in cells, increasing sensitivity to PARP inhibitor and DNA-damaging drugs. Through qPCR and WB assays, we found the same trend: DNA damage response-related protein ATM was down-regulated after BCAT1overexpression, which preliminarily explained why DNA damage was increased after BCAT1overexpression. After exogenous supplementation with the aKG analog DM-aKG, the enhancement of DNA damage caused by overexpression of BCAT1can be reversed. In summary, this study indicated that CN-AML patients with high BCAT1expression had poor prognosis. BCAT1plays the role as oncogene, can induce DNA damage that renders AML cells sensitive to PARP inhibition and DNA damage agents, and can be used as a novel therapeutic option for AML. Figure Disclosures No relevant conflicts of interest to declare.
Scrapie in France: some possible predisposing factors in the naturally-acquired disease of sheep.

Jacqueline Chatelain,Nicole Delasnerie-Laupretre,Françoise Cathala,P. Brown

DOI: https://doi.org/10.1016/0378-1135(83)90045-7

IF: 3.246

1983-10-01

Veterinary Microbiology

Abstract:
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells

Haruka Hiroki,Yuko Ishii,Jinhua Piao,Yui Namikawa,Mitsuko Masutani,Hiroaki Honda,Koshi Akahane,Takeshi Inukai,Tomohiro Morio,Masatoshi Takagi

DOI: https://doi.org/10.1038/s41598-023-33852-2

2023-05-10

Abstract:BCR/ABL1 causes dysregulated cell proliferation and is responsible for chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL). In addition to the deregulatory effects of its kinase activity on cell proliferation, BCR/ABL1 induces genomic instability by downregulating BRCA1. PARP inhibitors (PARPi) effectively induce cell death in BRCA-defective cells. Therefore, PARPi are expected to inhibit growth of CML and Ph1-ALL cells showing downregulated expression of BRCA1. Here, we show that PARPi effectively induced cell death in BCR/ABL1 positive cells and suppressed colony forming activity. Prevention of BCR/ABL1-mediated leukemogenesis by PARP inhibition was tested in two in vivo models: wild-type mice that had undergone hematopoietic cell transplantation with BCR/ABL1-transduced cells, and a genetic model constructed by crossing Parp1 knockout mice with BCR/ABL1 transgenic mice. The results showed that a PARPi, olaparib, attenuates BCR/ABL1-mediated leukemogenesis. One possible mechanism underlying PARPi-dependent inhibition of leukemogenesis is increased interferon signaling via activation of the cGAS/STING pathway. This is compatible with the use of interferon as a first-line therapy for CML. Because tyrosine kinase inhibitor (TKI) monotherapy does not completely eradicate leukemic cells in all patients, combined use of PARPi and a TKI is an attractive option that may eradicate CML stem cells.
Augmentation ureterocystoplasty: is it the preferred choice?

P. Carneiro,J. Binyamini,M. Sofer,J. Ben‐Chaim

DOI: https://doi.org/10.4314/EAMJ.V82I5.9314

2005-05-01

East African Medical Journal

Abstract:BACKGROUND Various methods of urinary bladder augmentation have been attempted in order to try and achieve adequate bladder capacity, urinary continence, control urinary tract infection and preserve the upper urinary tract; however, long-term complications have been unavoidable. OBJECTIVE To evaluate our experience with ureterocystoplasty as to whether it is the preferred method for bladder augmentation to achieve continence and preserve the upper urinary tract. DESIGN Retrospective study. SETTING Paediatric urology unit, Dana Children's hospital, Tel Aviv Medical Center (affiliated to the Sackler School of Medicine), Tel Aviv University. SUBJECTS Four children; three girls, one boy, mean age 7.3, range (3-14) years. Two had neurogenic bladder due to occult spinal dysrraphism, the other two had non-neurogenic neurogenic bladder. The indications for surgery were urinary incontinence with recurrent urinary tract infections in all patients, one also had upper tract dilatation. INTERVENTIONS All underwent augmentation ureteroplasty, two required nephrectomy due to non-functioning kidney, two required clean intermittent catheterizatiom postoperatively. MAIN OUTCOME MEASURES Urinary continence, bladder capacity, vesicoureteral reflux, renal function tests, urinary tract infection rate and surgical complications encountered. RESULTS In a mean follow-up period of 24 (6-46) months, all of the patients achieved urinary continence, two of the patients who have a normal bladder outlet are continent and void spontaneously with no residual urine. The other two patients are continent on clean intermittent catheterization. Only one episode of urinary tract infection was seen, none of the patients are currently on prophylactic antibiotics. The urinary bladder in all patients is spherical with good capacity and no vesicoureteral reflux was demonstrated. The upper urinary tracts are stable and the renal function tests are normal. CONCLUSION Ureterocystoplasty is our preferred choice of bladder augmentation in patients with small, inelastic, poor compliant bladder with at least a moderately dilated ureter. Complications normally seen with enterocystoplasties are minimal.
PARP10 is highly expressed and associated with inferior outcomes in acute myeloid leukemia

Ling Wang,Chuang Jiang,Dandan Hu

DOI: https://doi.org/10.18632/aging.204832

2023-07-30

Aging

Abstract:Acute myeloid leukemia is a heterogeneous disease of the hematopoietic system, which possesses a poor prognosis; thus, the identification of novel molecular markers is urgently needed to better define the risk stratification and optimize treatment therapies for this disease. Here, we investigated the roles of the PARP family genes in AML by analyzing their mRNA expression profiles and their association with clinical features using data from TCGA and GSE. Our results showed that PARP10 was...

cell biology,geriatrics & gerontology,gerontology
Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia

Mara W Rosenberg,Samantha L Savage,Christopher A Eide,Anna Reister Schultz,Rachel J Cook,Richard D Press,Carole Rempfer,Garrett Eickelberg,Beth Wilmot,Shannon K McWeeney,Jeffrey W Tyner,Brian J Druker,Cristina E Tognon

DOI: https://doi.org/10.1101/mcs.a006218

2022-10-28

Abstract:The Philadelphia chromosome (Ph) resulting from the t(9;22) translocation generates the oncogenic BCR::ABL1 fusion protein that is most commonly associated with chronic myeloid leukemia (CML) and Ph-positive (Ph+) acute lymphoblastic leukemia (ALL). There are also rare instances of patients (≤1%) with newly diagnosed acute myeloid leukemia (AML) that harbor this translocation (Paietta et al., Leukemia 12: 1881 [1998]; Keung et al., Leuk Res 28: 579 [2004]; Soupir et al., Am J Clin Pathol 127: 642 [2007]). AML with BCR::ABL has only recently been provisionally classified by the World Health Organization as a diagnostically distinct subtype of AML. Discernment from the extremely close differential diagnosis of myeloid blast crisis CML is challenging, largely relying on medical history rather than clinical characteristics (Arber et al., Blood 127: 2391 [2016]). To gain insight into the genomic features underlying the evolution of AML with BCR::ABL, we identified a patient presenting with a high-risk myelodysplastic syndrome that acquired a BCR::ABL alteration after a peripheral blood stem cell transplant. Serial samples were collected and analyzed using whole-exome sequencing, RNA-seq, and ex vivo functional drug screens. Persistent subclones were identified, both at diagnosis and at relapse, including an SF3B1p.Lys700Glu mutation that later cooccurred with an NRASp.Gly12Cys mutation. Functional ex vivo drug screening performed on primary patient cells suggested that combination therapies of ABL1 with RAS or PI3K pathway inhibitors could have augmented the patient's response throughout the course of disease. Together, our findings argue for the importance of genomic profiling and the potential value of ABL1 inhibitor-inclusive combination treatment strategies in patients with this rare disease.
P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA

F. G. Ruecker,A. Corbacioglu,F. Theis,M. Christopeit,U. Germing,G. Wulf,M. Abu Samra,L. Teichmann,M. Lübbert,M. W. Kühn,M. Bentz,J. Westermann,L. Bullinger,V. I. Gaidzik,E. Jahn,M. Gröger,S. Kapp-Schwoerer,D. Weber,F. Thol,M. Heuser,A. Ganser,H. Döhner,K. Döhner

DOI: https://doi.org/10.1097/01.hs9.0000844680.77570.26

2022-01-01

HemaSphere

Abstract:Background: Mutations of CEBPA (CEBPAmut) are present in ~5-10% of newly diagnosed adult acute myeloid leukemia (AML), and approximately half of the patients (pts) exhibit biallelic mutations (CEBPAbi). CEBPAbi defines a distinct entity within the 2016 WHO classification and is categorized as favorable in the 2017 risk stratification by the European LeukemiaNet. CEBPAmut can be divided into basic leucine zipper domain (bZIP) or transcription activation domains (TAD) mutations, respectively. Recent studies have demonstrated CEBPAbZIP mutations, in particular in-frame mutations (CEBPAbZIP-inf), to be associated with favorable outcome, regardless of mono- or biallelic status. Aims: To evaluate the prognostic impact of CEBPAbZIP, in particular CEBPAbZIP-inf mutations in AML. Methods: Investigating a cohort of 454 intensively treated CEBPA mutated AML pts entered into the AMLSG BiO Registry study (NCT01252485). Results: Of the 454 pts, 223 had CEBPAbi and 231 monoallelic CEBPA mutations (CEBPAsm) affecting bZIP in 78 pts or TAD in 153 pts. Genotypes differed significantly with regard to clinical and genetic features: CEBPAbi pts were younger than CEBPAsmbZIP and CEBPAsmTAD (median age in yrs: 52 vs 59 vs 60; P<.001), had a higher rate of de novo AML (97% vs 81% vs 84%; P<.001), lower platelet counts (median G/l 36 vs 57 vs 52; P<.001), higher peripheral blood (PB) blast counts (median 71% vs 60% vs 44%; P<.001), and showed an inverse correlation with FLT3 internal tandem duplication (FLT3-ITD) and NPM1 mutation (NPM1mut) (6% vs 21% vs 35% and 0% vs 26% vs 50%; P<.001 each). Outcome analysis revealed a significant improved overall (OS) and event-free survival (EFS) for CEBPAbi with no difference between CEBPAsmbZIP and CEBPAsmTAD (5-year OS: 62% vs 42% vs 51%; P<.001, 5-year EFS: 47% vs 27% vs 43%; P<.022). Subgroup specific analysis within CEBPAsmbZIP revealed an improved outcome for CEBPAbZIP-inf pts (n=46) (5-year OS: 52% vs 29%; P=.001, and 5-year EFS: 34% vs 18%; P=.018). To further address the impact of CEBPAbZIP-inf, pts were categorized as CEBPAbZIP-inf (n=250), irrespective of the allelic status, vs all others (CEBPAother) (n=204). CEBPAbZIP-inf pts were younger (median age in yrs: 52 vs 62; P<.001), had a higher rate of de novo AML (97% vs 81%; P<.001), lower platelet counts (median G/l 36 vs 53; P<.001), higher white blood cell (WBC) (median G/l 25.4 vs 16.1; P=.029), and higher PB blast counts (median 72% vs 46%; P<.001); FLT3-ITD and NPM1mut were less common in CEBPAbZIP-inf pts (9% vs 30% and 3% vs 44%; P<.001 each). CEBPAbZIP-inf exhibited a significant improved OS (5-year OS: 60% vs 48%; P<.001) and EFS (5-year EFS: 47% vs 37%; P=.007); in multivariate Cox models for OS and EFS, including allogeneic hematopoietic cell transplantation (HCT) in first complete remission as time-dependent covariate, age (HR: 1.50; P<.001), WBC (HR: 1.40; P=.018), and adverse cytogenetics (HR: 2.33; P=.010) were unfavorable factors for OS, whereas NPM1mut (HR: 0.63; P=.040), HCT (HR: 0.46; P=.010), and CEBPAbZIP-inf (HR: 0.59; P=.007) revealed as favorable. For EFS, age (HR: 1.19; P=.002), WBC (HR: 1.30; P=.028), and FLT3-ITD (HR: 1.83; P=.003) were unfavorable, whereas NPM1mut (HR: 0.65; P=.028) and HCT (HR: 0.33; P<.001) were favorable. Summary/Conclusion: In this cohort of 454 CEBPA mutated adult AML pts, CEBPAbZIP-inf was associated with specific clinical and genetic characteristics. Furthermore, CEBPAbZIP-inf pts had a significantly superior outcome irrespective of the allelic status. This study confirms recent findings suggesting a prognostic role of this mutation type. FGR and AC contributed equally
BCRP mRNA and FLT3-ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype

Barbara Nasiłowska-Adamska,Krzysztof Warzocha,Iwona Solarska,Katarzyna Borg,Barbara Pieńkowska-Grela,Anna Czyż

DOI: https://doi.org/10.1111/ejh.12913

Abstract:Purpose: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) is aberration associated with poor prognosis in AML. We have analyzed the expression of MDR-1, MRP-1, and BCRP mRNA in relation to FLT3-ITD in 100 AML adult patients with normal and intermediate karyotype. Methods: The RQ-PCR method was performed to assess the expression of MDR-1, MRP-1, and BCRP mRNA, and the results were presented as coefficients calculated using an intermediate method according to Pfaffl's rule. Results: According to univariate analysis, the following pretreatment variables negatively influenced disease-free survival (DFS): WBC count ≥25×109 /L (P=.037), MRP-1 mRNA ≥1.6818 (P=.028), BCRP mRNA ≥1.1892 (P=.004), FLT3-ITD (P=.005) and overall survival (OS): WBC count ≥25×109 /L (P=.031), MRP-1 mRNA ≥1.6818 (P=.01), BCRP mRNA ≥1.1892 (P=.01), FLT3-ITD (P=.001). When all prognostic variables were pooled into a multivariate model, we found that WBC count ≥25×109 /L (P=.026) and BCRP mRNA ≥1.1892 (P=.011). We observed trend in negative influence of FLT3-ITD on DFS (P=.057). BCRP mRNA ≥1.1892 (P=.035) and FLT3-ITD (P=.006) negatively, independently influenced the OS. Conclusions: The high expressions of BCRP mRNA calculated with Pfaffl's rule and FLT3-ITD are independent poor risk factors in adult patients with AML and intermediate or normal karyotype.
'Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting

Dikshat Gopal Gupta,Neelam Varma,Sreejesh Sreedharanunni,Sarki Abba Abdulkadir,Shano Naseem,Man Updesh Singh Sachdeva,Jogeshwar Binota,Parveen Bose,Pankaj Malhotra,Alka Khadwal,Subhash Varma

DOI: https://doi.org/10.1038/s41416-023-02294-y

Abstract:Background: Early detection of BCR::ABL1-like ALL could impact treatment management and improve the overall survival/outcome. BCR::ABL1-like ALL cases are characterised by diverse genetic alterations activating cytokine receptors and kinase signalling. Its detection is still an unmet need in low-middle-income countries due to the unavailability of a patented TLDA assay. Methods: This study's rationale is to identify BCR::ABL1-like ALLs using the PHi-RACE classifier, followed by the characterisation of underlying adverse genetic alterations in recurrent gene abnormalities negative (RGAneg) B-ALLs (n = 108). Results: We identified 34.25% (37/108) BCR::ABL1-like ALLs using PHi-RACE classifier, characterised by TSLPR/CRLF2 expression (11.58%), IKZF1 (Δ4-7) deletion (18.9%) and chimeric gene fusions (34.61%). In overexpressed TSLPR/CRLF2 BCR::ABL1-like ALLs, we identified 33.33% (1/3) CRLF2::IGH and 33.33% (1/3) EPOR::IGH rearrangements with concomitant JAK2 mutation R683S (50%). We identified 18.91% CD13 (P = 0.02) and 27.02% CD33 (P = 0.05) aberrant myeloid markers positivity, which was significantly higher in BCR::ABL1-like ALLs compared to non-BCR::ABL1-like ALLs. MRD positivity was considerably higher (40% in BCR::ABL1-like vs. 19.29% in non-BCR::ABL1-like ALLs). Conclusions: With this practical approach, we reported a high incidence of BCR::ABL1-like ALLs, and a lower frequency of CRLF2 alteration & associated CGFs. Recognising this entity, early at diagnosis is crucial to optimise personalised treatment strategies.
Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival

Pablo Romero-Morelos,Ana Lilia González-Yebra,Anaid Herrerías-García,Francisco Arath Ruíz-Velázquez,Luis Jonathan Bueno-Rosario,Beatríz González-Yebra

DOI: https://doi.org/10.3390/genes15050567

IF: 4.141

2024-04-29

Genes

Abstract:Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the presence of the Philadelphia chromosome, a product of the reciprocal translocation t(9;22)(q34;q11), in the BCR and ABL genes. These rearrangements in both genes lead to the formation of various fusion mRNA products, with preferential expression of b2a2, b3a2, and other BCR::ABL1 mRNA variants, combined with additional chromosomal abnormalities. Notably, the distribution and frequency of different mRNA variants vary in different populations. However, studies concerning this in Mexico are limited, and the results have been inconclusive. This study therefore aimed to determine the distribution of BCR::ABL1 mRNA variants in different clinical phases of CML and their effect on hematological parameters and patient survival. This study included 33 patients, whose demographic, clinical, and molecular data on BCR::ABL1 mRNA variants and hematological parameters were collected to identify potential associations. A total of 84.8% (n = 28) of patients had BCR::ABL1 translocation and increased platelet and basophil counts. The most frequent mRNA variant was b3a2 (64.3%), followed by b2a2 (28.6%) and e1a2 (3.6%). Concerning the clinical phases of CML, 75.8% (n = 25), 21.2% (n = 7), and 3% (n = 1) of patients were in the chronic, blast, and accelerated phases, respectively. Moreover, the b3a2 mRNA variant was more commonly identified in patients in the chronic phase. No correlation was observed between mRNA variant expression and patient survival. However, b2a2 was indicative of patients with longer survival as well as those treated with imatinib or nilotinib. Additionally, platelet count could be a marker of BCR::ABL1 translocation.

genetics & heredity
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients

Lenka Hovorkova,Lucie Winkowska,Justina Skorepova,Manuela Krumbholz,Adela Benesova,Vaclava Polivkova,Julia Alten,Michela Bardini,Claus Meyer,Rathana Kim,Toby N Trahair,Emmanuelle Clappier,Sabina Chiaretti,Michelle Henderson,Rosemary Sutton,Lucie Sramkova,Jan Stary,Katerina Machova Polakova,Rolf Marschalek,Markus Metzler,Giovanni Cazzaniga,Gunnar Cario,Jan Trka,Marketa Zaliova,Jan Zuna

DOI: https://doi.org/10.1186/s12943-024-02053-4

2024-07-05

Abstract:Background: The BCR::ABL1 is a hallmark of chronic myeloid leukemia (CML) and is also found in acute lymphoblastic leukemia (ALL). Most genomic breaks on the BCR side occur in two regions - Major and minor - leading to p210 and p190 fusion proteins, respectively. Methods: By multiplex long-distance PCR or next-generation sequencing technology we characterized the BCR::ABL1 genomic fusion in 971 patients (adults and children, with CML and ALL: pediatric ALL: n = 353; pediatric CML: n = 197; adult ALL: n = 166; adult CML: n = 255 patients) and designed "Break-App" web tool to allow visualization and various analyses of the breakpoints. Pearson's Chi-Squared test, Kolmogorov-Smirnov test and logistic regression were used for statistical analyses. Results: Detailed analysis showed a non-random distribution of breaks in both BCR regions, whereas ABL1 breaks were distributed more evenly. However, we found a significant difference in the distribution of breaks between CML and ALL. We found no association of breakpoints with any type of interspersed repeats or DNA motifs. With a few exceptions, the primary structure of the fusions suggests non-homologous end joining being responsible for the BCR and ABL1 gene fusions. Analysis of reciprocal ABL1::BCR fusions in 453 patients showed mostly balanced translocations without major deletions or duplications. Conclusions: Taken together, our data suggest that physical colocalization and chromatin accessibility, which change with the developmental stage of the cell (hence the difference between ALL and CML), are more critical factors influencing breakpoint localization than presence of specific DNA motifs.
Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease

Magda Zanelli,Valentina Fragliasso,Giuseppe Gaetano Loscocco,Francesca Sanguedolce,Giuseppe Broggi,Maurizio Zizzo,Andrea Palicelli,Stefano Ricci,Elisa Ambrogi,Giovanni Martino,Sara Aversa,Francesca Coppa,Pietro Gentile,Fabrizio Gozzi,Rosario Caltabiano,Nektarios Koufopoulos,Aleksandra Asaturova,Luca Cimino,Alberto Cavazza,Giulio Fraternali Orcioni,Stefano Ascani

DOI: https://doi.org/10.3389/fcell.2024.1391078

IF: 5.5

2024-03-27

Frontiers in Cell and Developmental Biology

Abstract:Myeloproliferative neoplasms (MPNs) are subdivided into Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) and Ph-negative MPNs. BCR::ABL1 translocation is essential for the development and diagnosis of CML; on the other hand, the majority of Ph-negative MPNs are characterized by generally mutually exclusive mutations of Janus kinase 2 ( JAK2 ), calreticulin ( CALR ), or thrombopoietin receptor/myeloproliferative leukemia ( MPL ). CALR mutations have been described essentially in JAK2 and MPL wild-type essential thrombocythemia and primary myelofibrosis. Rarely coexisting CALR and MPL mutations have been found in Ph-negative MPNs. BCR::ABL1 translocation and JAK2 mutations were initially considered mutually exclusive genomic events, but a discrete number of cases with the combination of these genetic alterations have been reported. The presence of BCR::ABL1 translocation with a coexisting CALR mutation is even more uncommon. Herein, starting from a routinely diagnosed case of CALR -mutated primary myelofibrosis subsequently acquiring BCR::ABL1 translocation, we performed a comprehensive review of the literature, discussing the clinicopathologic and molecular features, as well as the outcome and treatment of cases with BCR::ABL1 and CALR co-occurrence.

cell biology,developmental biology
Cotinine, a major metabolite of nicotine, is detectable in follicular fluids of passive smokers in in vitro fertilization therapy.

M. Zenzes,T. Reed,Peng Wang,Julia Klein

DOI: https://doi.org/10.1016/S0015-0282(16)58577-X

IF: 6.7

1996-10-01

Fertility and Sterility

Abstract:
Expression of HOTAIR and PTGS2 as potential biomarkers in chronic myeloid leukemia patients in Brazil

Ana Paula Kubaski Benevides,Anelis Maria Marin,Denise K. Wosniaki,Rafaela Noga Oliveira,Gabriela Marino Koerich,Bianca Nichele Kusma,Eduardo Cilião Munhoz,Dalila Luciola Zanette,Mateus Nóbrega Aoki

DOI: https://doi.org/10.3389/fonc.2024.1443346

IF: 4.7

2024-10-11

Frontiers in Oncology

Abstract:Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm in which all the patients has the translocation ( 9;22 ) that generates de BCR::ABL1 tyrosine kinase. Despite this disease possessing a good biomarker ( BCR::ABL1 transcripts level) for diagnosis and prognosis, many studies has been performed to investigate other molecules, such as the long noncoding RNAs (lncRNAs) and mRNAs, as potential biomarkers with the aim of predicting a change in BCR::ABL1 levels and as an associated biomarker. A RNAseq was performed comparing 6 CML patients with high BCR::ABL1 expression with 6 healthy control individuals, comprising the investigation cohort to investigate these molecules. To validate the results obtained by RNAseq, samples of 87 CML patients and 42 healthy controls were used in the validation cohort by RT-qPCR assays. The results showed lower expression of HOTAIR and PTGS2 in CML patients. The HOTAIR expression is inversely associated with BCR::ABL1 expression in imatinib-treated CML patients, and to PTGS2 showing that CML patients with high BCR::ABL1 expression showed reduced PTGS2 expression.

oncology
Graphical analysis of multiple inert gas elimination data.

W. E. Stewart,S. Mastenbrook

DOI: https://doi.org/10.1152/JAPPL.1983.55.1.32

1983-07-01

Abstract:A plot of measured retention-excretion ratios [(Ri/Ei)obs] vs. reciprocal solubility (1/lambda i) for selected inert gases allows quick detection of shunt and ventilation-perfusion (V/Q) inhomogeneity in the lung. We derive simple rules for constructing a smooth R/E function from the data, using a multicompartmental model of the lung. If mixed venous inert gas measurements are available, the values [lambda i(1-Ri)/Ei]obs for the infused gases can be used to estimate the overall VT/QT ratio and provide an additional test of the consistency of the data. For any set of equilibrium compartments ventilated and perfused in parallel, we show that d(R/E)/d(1/lambda) cannot be negative, nor can d2(R/E)/d(1/lambda)2 be greater than zero. A rectilinear R/E function implies a narrow distribution of V/Q among the gas exchange compartments, whereas a downward-concave curve implies a broader distribution. The shunt perfusion and dead-space ventilation can be estimated from the asymptotes of the R/E function. The range of V/Q for the gas exchange compartments can also be bracketed if a well-defined region of curvature is present in the graph. Finally, from the R/E vs. 1/lambda graph and (if mixed venous data are available) from the lambda(1-R)/E values, we can determine quickly whether the data deserve the detailed numerical analysis outlined in our companion paper.
Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis

Lara Boucher,Nathalie Sorel,Christophe Desterke,Mélanie Chollet,Laura Rozalska,Maria Pilar Gallego Hernanz,Emilie Cayssials,Anna Raimbault,Annelise Bennaceur-Griscelli,Ali G. Turhan,Jean-Claude Chomel

DOI: https://doi.org/10.3390/ijms242015441

IF: 5.6

2023-10-23

International Journal of Molecular Sciences

Abstract:Acute myeloid leukemia (AML) with BCR::ABL1 has recently been recognized as a distinct subtype in international classifications. Distinguishing it from myeloid blast crisis chronic myeloid leukemia (BC-CML) without evidence of a chronic phase (CP), remains challenging. We aimed to better characterize this entity by integrating clonal architecture analysis, mutational landscape assessment, and gene expression profiling. We analyzed a large retrospective cohort study including CML and AML patients. Two AML patients harboring a BCR::ABL1 fusion were included in the study. We identified BCR::ABL1 fusion as a primary event in one patient and a secondary one in the other. AML-specific variants were identified in both. Real-time RT-PCR experiments demonstrated that CD25 mRNA is overexpressed in advanced-phase CML compared to AML. Unsupervised principal component analysis showed that AML harboring a BCR::ABL1 fusion was clustered within AML. An AML vs. myeloid BC-CML differential expression signature was highlighted, and while ID4 (inhibitor of DNA binding 4) mRNA appears undetectable in most myeloid BC-CML samples, low levels are detected in AML samples. Therefore, CD25 and ID4 mRNA expression might differentiate AML with BCR::ABL1 from BC-CML and assign it to the AML group. A method for identifying this new WHO entity is then proposed. Finally, the hypothesis of AML with BCR::ABL1 arising from driver mutations on a BCR::ABL1 background behaving as a clonal hematopoiesis mutation is discussed. Validation of our data in larger cohorts and basic research are needed to better understand the molecular and cellular aspects of AML with a BCR::ABL1 entity.

biochemistry & molecular biology,chemistry, multidisciplinary
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability

Michele Massimino,Stefania Stella,Elena Tirrò,Maria Stella Pennisi,Fabio Stagno,Silvia Rita Vitale,Chiara Romano,Cristina Tomarchio,Nunziatina Laura Parrinello,Livia Manzella,Francesco Di Raimondo,Paolo Vigneri

DOI: https://doi.org/10.2147/OTT.S413825

2023-10-03

Abstract:Purpose: Chronic Myeloid Leukemia (CML) is a clonal disorder of the hematopoietic stem cell caused by expression of the BCR::ABL1 oncoprotein. High BCR::ABL1 levels have been associated to proliferative advantage of leukemic cells, blast crisis progression and tyrosine kinase inhibitors (TKIs) inefficacy. We have previously shown that high BCR::ABL1/GUSIS transcripts measured at diagnosis are associated with inferior responses to standard dose Imatinib (IM). However, the mechanisms underlying the higher rates of disease progression and development of TKIs resistance dependent on elevated BCR::ABL1 levels remain unclear. Methods: Leukemic cells were collected from CML patients showing, at diagnosis, high or low BCR::ABL1/GUSIS. BCR::ABL1 expression levels were measured using real-time PCR. Short-term culture and long-term culture-initiating cells assays were employed to investigate the role of BCR::ABL1 gene-expression levels on proliferation, clonogenicity, signal transduction, TKIs responsiveness and self-renewal ability. Cell division was performed by carboxyfluorescein-succinimidyl ester (CFSE) assay. Results: We found that BCR::ABL1 oncogene expression levels correlate in both PMNs and CD34+ cells. Furthermore, high oncogene levels increased both proliferation and anti-apoptotic signaling via ERK and AKT phosphorylation. Moreover, high BCR::ABL1 expression reduced the clonogenicity of leukemic CD34+ cells and increased their sensitivity to high doses IM but not to those of dasatinib. Furthermore, we observed that high BCR::ABL1 levels are associated with a reduced self-renewal of primitive leukemic cells and, also, that these cells showed comparable TKIs responsiveness with cells expressing lower BCR::ABL1 levels. Interestingly, we found a direct correlation between high BCR::ABL1 levels and reduced number of quiescent leukemic cells caused by increasing their cycling. Conclusion: Higher BCR::ABL1 levels improving the proliferation, anti-apoptotic signaling and reducing self-renewal properties cause an increased expansion of leukemic clone.
Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia with Philadelphia Chromosome Positive And/or Bcr-Abl Positive in Adult

Ying Wang,Min Gu,Yingchang Mi,Lugui Qiu,Shougeng Bian,Jianxiang Wang

DOI: https://doi.org/10.1007/s12185-011-0953-1

2011-01-01

International Journal of Hematology

Abstract:Knowledge of mixed phenotype acute leukemia (MPAL) with t(9;22)(q34;q11.2) and/or bcr-abl (Ph-positive MPAL) is limited. In this report, we review 21 adult patients with Ph-positive and/or bcr-abl positive MPAL. They were predominantly male, and presented with high WBC counts; 61.9% patients had WBC counts higher than 30 × 10(9)/L, and 33.3% patients had WBC counts higher than 100 × 10(9)/L. Electron microscopy (EM)-determined positivity for myeloperoxidase (MPO) should be considered for the classification of acute leukemia because MPO was positive by EM and flow cytometry only in 14.3% of cases in our study. Six cases (30.0%) had additional chromosome aberrations. Expression of p190(bcr-abl) was more common than that of p210(bcr-abl). There was no difference in characteristics between the p190(bcr-abl) positive and p210(bcr-abl) positive groups. The overall complete remission (CR) rate was 81.0%. Females, and patients with high WBC (>100 × 10(9)/L) at baseline had lower CR rate (57.1, 57.1%, respectively). The treatment outcome of Ph-positive MPAL is poor; the 1-year overall survival (OS) and relapse-free survival (RFS) rate were 28.0 and 18.0%, respectively. Imatinib and allogeneic hematopoietic stem cell transplantation can improve survival with Ph-positive MPAL.
Distinct Outcomes, ABL1 Mutation Profile, and Transcriptome Features Between P190 and P210 Transcripts in Adult Philadelphia-positive Acute Lymphoblastic Leukemia in the TKI Era

Shi Ting,Xie Mixue,Chen Li,Yuan Wei,Wang Yungui,Huang Xin,Xie Wanzhuo,Meng Haitao,Lou Yinjun,Yu Wenjuan,Tong Hongyan,Ye Xiujin,Huang Jinyan,Jin Jie,Zhu Honghu

DOI: https://doi.org/10.1186/s40164-022-00265-2

2022-01-01

Abstract:Background The differential signaling and outcome of patients with p190 or p210 transcripts of BCR-ABL1 have been systematically investigated in chronic myeloid leukemia rather than in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). Methods We analyzed the outcomes and ABL1 mutation profiles in 305 consecutive adult patients with Ph + ALL treated with chemotherapy plus tyrosine kinase inhibitors. We also studied transcriptome features in two newly diagnosed patients with p190 and p210 using single-cell RNA sequencing (scRNA-seq). Results P190 and p210 were found in 199 (65%) and 106 (35%) patients, respectively. Compared to patients with p190, a higher white blood cell count ( p = 0.05), platelet count ( p = 0.047), BCR-ABL1 transcript level ( p < 0.001 ), and lower bone marrow blasts ( p = 0.003) were found in patients with p210. Patients with p210 had fewer types of ABL1 mutations (4 vs. 16) and a higher prevalence of T315I and E225K/V mutations (91.3% vs. 68.6%; p = 0.031). Patients with p210 had a similar complete remission rate (91.0% vs . 90.1%; p = 0.805) but a lower complete molecular remission rate at 1 month (9.9% vs. 22.0%; p = 0.031) compared with p190. Patients with p210 had lower 3-year overall survival (OS) and disease-free survival (DFS) rates than those with p190 (3-year DFS: 10.4% vs. 9.2%, p = 0.069, 3-year OS: 44.3% vs. 38.2%, p = 0.018, respectively). Multivariate analysis revealed that p210 was independently associated with worse OS [HR 1.692 (95% CI 1.009–2.838), p = 0.046]. Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) was associated with a better prognosis in patients with p210 ( p < 0.0001). In addition, scRNA-seq data showed distinct molecular and cellular heterogeneity between bone marrow cells of the two transcripts. Conclusions Ph + ALL patients with p190 and p210 had different clinical characteristics, outcomes, ABL1 mutation profiles, and transcriptome features. Allo-HSCT could improve the outcomes of patients with p210.

The chest wall.

High Expression of BCAT1 Sensitizes AML Cells to PARP Inhibitor by Suppressing DNA Damage Response

High Expression of BCAT1 Promotes Acute Myeloid Leukemia Progression and Sensitize to PARP Inhibitor

Scrapie in France: some possible predisposing factors in the naturally-acquired disease of sheep.

Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells

Augmentation ureterocystoplasty: is it the preferred choice?

PARP10 is highly expressed and associated with inferior outcomes in acute myeloid leukemia

Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia

P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA

BCRP mRNA and FLT3-ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype

'Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting

Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival

Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients

Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease

Cotinine, a major metabolite of nicotine, is detectable in follicular fluids of passive smokers in in vitro fertilization therapy.

Expression of HOTAIR and PTGS2 as potential biomarkers in chronic myeloid leukemia patients in Brazil

Graphical analysis of multiple inert gas elimination data.

Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis

High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability

Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia with Philadelphia Chromosome Positive And/or Bcr-Abl Positive in Adult

Distinct Outcomes, ABL1 Mutation Profile, and Transcriptome Features Between P190 and P210 Transcripts in Adult Philadelphia-positive Acute Lymphoblastic Leukemia in the TKI Era